SinoMab Bioscience Ltd. 3681

Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease activity (28.8%; CLASI-70) than at week 24 (19.0% and 21.7%, respectively)Rapid onset: Participants that switched from placebo to litifilimab experienced improvements in skin disease activity in as early as four weeks -- consistent with results seen in participants who started

NEW YORK, October 02, 2026--Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent.

Key Stats for UnitedHealth StockCurrent Price: $365. 20Target Price (Mid): ~$586Street Target: ~$482Potential Total Return: ~61%Annualized IRR: ~12% / yearWhat Happened?UnitedHealth Group (UNH:NYSE) is shutting Medicare Advantage plans that cover about 390,000 people for 2027, a company spokesperson told Bloomberg on October 1.

Traders are reportedly pairing Robinhood’s (NASDAQ: $HOOD) tokenized stocks with memecoins in liquidity pools...

European equities traded in the US as American depositary receipts were trending higher late Friday

The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease (LOPD) were presented at the 31st Annual Congress of the World Muscle Society (WMS), in Hiroshima, Japan.

ANNOUNCEMENT NO. 3162 October 2026 ChemoMetec A/S has completed the share buyback programme announced in company announcement no. 309 dated 15 May 2026. The programme provided for the repurchase of up to 500,000 shares for a total consideration of up to DKK 100 million. Under the programme, ChemoMetec A/S repurchased a total of 239,950 shares for a total consideration of DKK 99,998,735. Following completion of the programme, ChemoMetec A/S holds a total of 239,950 treasury shares, corresponding

Major corporations including Boeing, Eli Lilly, and McDonald’s have added the roles since 2020, the report from Crist Kolder finds.

Asian equities traded in the US as American depositary receipts were trending higher Friday morning,

Ivonescimab is currently in development as a combination drug across several types of solid tumours.

IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.

LONDON, October 02, 2026-- FORM 8.3

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026. Title: Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor

Global bond markets have recently steadied after a sharp sell off that pushed borrowing costs to their highest levels since 2002, and that pause is giving Australian biotech stocks fresh attention from investors hunting for focused growth themes rather than broad market bets. With balance sheets that look relatively reasonable and valuations that are not outright speculative, this basket of healthcare developers offers targeted exposure. This article examines three of the more notable biotech...

Ocular Therapeutix has delivered a steep 144.6% gain over the past three years, yet the stock is currently well off recent highs. That puts fresh focus on a basic question: Is the price investors see today adequately anchored to the company’s sales, given where the business is in its development path? The share price has climbed 144.6% over three years. This makes the link between that move and Ocular Therapeutix’s sales base a key issue for anyone reassessing the story now. The AXPAXLI...

Viking Therapeutics recently completed a US$225,000,000 convertible bond offering and a US$275,000,005 follow-on equity raise, soon after reporting past positive top-line results from its VK2735 obesity maintenance trial showing strong weight loss retention with less frequent dosing and a placebo-like safety profile. The company’s ability to pair compelling VK2735 maintenance data with substantial new financing highlights how clinical progress is being matched by balance sheet reinforcement...

Nvidia stock is on pace to close at a record high.

CPM logo CPM is a leading global provider of process equipment, engineered technologies and aftermarket parts and services serving customers across the food, fuel and industrial markets. With a global installed base and portfolio of industry-leading brands, CPM supports customers from new equipment and process solutions through parts, service, upgrades and ongoing equipment support. For more information, visit onecpm.com. Jeremy Patten Jeremy Patten has joined the CPM as Chief Executive Officer.